// App-Quantinova.ai

3065 : Combined Use of WT1 and Flow Cytometry Monitoring Can Promote Sensitivity of Predicting Relapse After Allogeneic HSCT without Affecting Specificity.

Researchers

Presenter

  • Chenhua Yan

Principal Investigators

  • Daihong Liu

  • Lanping Xu

  • Yanrong Liu

  • Kaiyan Liu

  • Yazhen Qin

  • Yu Wang

  • Xiaojun Huang

Medical Centers

  • Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

  • Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • WT1 Transcription Factor

Drug/Treatment

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved